BioCentury | Apr 6, 2021
Finance

VCs led by HBM, Samsara back single-asset Mitsubishi Tanabe spinout Mineralys with $40M for hypertension program

...Inc. (NASDAQ:PHAT), which holds territorial rights to gastrointestinal drug vonoprazan from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502); and Exalys Therapeutics Inc....
BioCentury | Jul 17, 2020
Finance

July 16 Quick Takes: Biotech stocks fare worse than others in STAR tumble; plus BioAtla, Exalys, Virometix, Biose, Spirea

...in specific locations. Exalys debuts with $15M, Eisai deal Domain Associates and Catalys Pacific launched Exalys Therapeutics Inc....
Items per page:
1 - 2 of 2
BioCentury | Apr 6, 2021
Finance

VCs led by HBM, Samsara back single-asset Mitsubishi Tanabe spinout Mineralys with $40M for hypertension program

...Inc. (NASDAQ:PHAT), which holds territorial rights to gastrointestinal drug vonoprazan from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502); and Exalys Therapeutics Inc....
BioCentury | Jul 17, 2020
Finance

July 16 Quick Takes: Biotech stocks fare worse than others in STAR tumble; plus BioAtla, Exalys, Virometix, Biose, Spirea

...in specific locations. Exalys debuts with $15M, Eisai deal Domain Associates and Catalys Pacific launched Exalys Therapeutics Inc....
Items per page:
1 - 2 of 2